Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section user-groups · Version 2026-09-01 · Cadence quarterly · Evidence class mixed · Sources 9 · Supersedes none
Domain: veterinary-diabetes-glucose-monitoring · Scope: public primary sources reachable by this repo's connectors, WebSearch and WebFetch. Excludes CPT descriptors (AMA-licensed and, per the regulatory finding in this report, not applicable to a veterinary-only device regardless), veterinary datasets (no US federal dataset exists), fda.gov guidance documents (intermittent bot mitigation), MAUDE narratives (no connector), and jurisdictions other than US and EU/UK (no connector exists for others).
Sourcing: One federal regulation (21 CFR 807.65(b)) and eight PubMed-indexed veterinary studies/guidelines, all read at abstract depth via literature-detail; every substantive line rests on exactly one source except the purchaser row's cost-barrier finding, which two independent, non-affiliated owner surveys nine years apart agree on.
The domain dossier flags its own user-groups section as "mostly not searched," with sourced content present only for the operator/patient complication record it borrowed from the reference-products section, and explicit gaps left for a veterinarian-specific guideline position, a technician-specific incentive, and clinic-side device economics. This report searches those gaps directly and adds sourced content to four of the five rows — prescriber, operator (split into owner and veterinary technician), purchaser, and payer — while confirming the patient row's existing welfare evidence with an independent retrieval. Two independent, non-affiliated owner surveys conducted nine years apart agree that cost is a recurring, substantial burden on the purchaser: a 2014 US survey of 834 diabetic-pet owners found treatment considered "expensive" by the majority of respondents, and a 2023 survey of 50 diabetic-pet owners using a flash glucose monitoring system found more than a third still described the device's cost as difficult to sustain long-term. Everything else below rests on exactly one source per line and is marked accordingly. No source located in this pass separates a veterinary technician's own incentives from a veterinarian's, and no source addresses clinic-side markup or margin on a monitoring device — both gaps the domain dossier had already named and which remain open here.
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
The most recent AAHA practice guideline for this condition states its own position on where monitoring responsibility sits: "An essential aspect of successful DM management is to ensure that the owner of a diabetic dog or cat is capable of administering insulin, recognizing the clinical signs of inadequately managed DM, and monitoring blood glucose levels at home, although this is ideal but not mandatory" [1] [single-source]. Read plainly, the guideline the prescriber works from treats owner-performed home monitoring as desirable rather than required, which sets the prescriber's incentive to encourage it without making its absence a departure from guideline care. The predecessor 2010 version of the same guideline exists in PubMed's record only as a title and metadata, with no abstract text retrievable from the record itself, so no substantive comparison between the two versions is made here [not retrieved beyond title/metadata].
Owner as operator, at home. In a UK cohort of 101 owners of insulin-treated diabetic dogs surveyed with the validated DIAQoL-pet tool, "eighty-four percent of owners reported negative impact of DM on QoL," with the specific areas of worst impact including "worry," "difficulties leaving dog with friends or family," "worry hypoglycemia," and "costs" [2] [single-source]. In a separate UK study of 38 recently diagnosed diabetic cats, 28 of 38 owners (74%) entered a home-blood-glucose-monitoring (HBGM) group after a standardised instruction session, and "HBGM was adopted successfully by most diabetic cat owners," with DIAQoL-pet scores — including owner worry about the disease, about hypoglycemia, and about cost — improving at 1, 3 and 6 months within the HBGM group but not within the non-HBGM group [3] [single-source · manufacturer]; that study discloses it "was supported by Zoetis, which sells glucometers for use in dogs and cats." A 2023 survey of 50 owners using a flash glucose monitoring system (FGMS) found the most challenging aspects of ownership to be "ensuring proper sensor fixation during the wearing period (47%)" and "preventing premature detachment (40%)" [4] [single-source].
Veterinary technician / clinic staff as operator, at sensor placement. A retrospective review of 34 diabetic dogs that had a 14-day FGMS placed found an overall complication incidence of 13/34 (38%), most frequently "mild dermatologic changes at the sensor site (18%)" [5] [single-source]. A separate retrospective review of 20 diabetic cats (33 sensor placements) found an overall complication incidence of 10/33 (30%), with early sensor detachment the most frequent finding at 15% [6] [single-source]. Neither study reports who performed the placement (technician versus veterinarian) or measures placement time, so the technician's own workload or incentive relative to the veterinarian's is not established by either source.
A 2014 internet-based survey of 834 US owners of diabetic dogs and cats reports plainly: "Treatment was considered expensive by the majority of owners" [7] [single-source]; the same survey found "cat owners were more likely to use home blood glucose monitoring" than dog owners, and reported satisfaction with diabetic control achieved at 66% among cat owners versus 50% among dog owners [7] [single-source]. A 2023 survey of 50 FGMS-using owners, run by a different research group nearly a decade later, found "36% of DPOs reported that the device cost was difficult to afford in the long term" and that "purchasing the sensor" itself was the third most commonly cited challenge, at 34% [4] [single-source]. These two surveys measure different things — general diabetes-treatment expense in 2014 versus one specific device's price in 2023 — but taken together they are two independent, non-affiliated sources agreeing that cost is a recurring purchaser concern across the decade separating them, which is stated plainly here without a marker; the individual percentages behind that agreement remain single-source each, as marked above.
Under 21 CFR 807.65(b), "a manufacturer of devices to be used solely for veterinary purposes" is exempt from the FDA device-establishment registration requirement that applies to human-labeled device manufacturers [8] [single-source]. No source located in this pass names any third-party payer for glucose-monitoring devices or blood-glucose-curve services in this domain: every owner-reported cost figure in the purchaser row above is described, in its own source, as coming from the owner's own funds rather than from an insurer or a public program, and no HCPCS, CPT, or federal coverage policy attaches to a device that sits entirely outside the FDA premarket-review structure those code families are built around.
A study of 10 healthy cats measured hourly for 10 hours, both at home and during hospitalisation, found "stress-induced hyperglycaemia was observed in the hospital," with "the acclimatisation cut-off time for the cats' return to euglycaemia" measured at 6 hours, and significantly elevated heart rate, respiratory rate, Cat Stress Score, glucose and cortisol in hospital versus at home (P<0.001) [9] [single-source]. Owners separately reported, in the same 2023 FGMS survey cited above, that "more than 80% of DPOs considered FGMS easier to use and less stressful and painful for the animal compared to blood glucose curves," and that "92% of DPOs reported that their pet had better diabetes control since using FGMS" [4] [single-source]. Set against that reported benefit, the same animals bear the complication burden documented in the operator section above — 38% of dog placements and 30% of cat placements experiencing a complication [5][6] — which is a cost the patient carries directly rather than one reported secondhand through an owner's perception.
[1] 2018 AAHA Diabetes Management Guidelines for Dogs and Cats — Journal of the American Animal Hospital Association (published 2018, month not given in the PubMed record; accessed 2026-09-01). PMID 29314873 — https://pubmed.ncbi.nlm.nih.gov/29314873/ [guideline] [2] Evaluation of a quality-of-life tool for dogs with diabetes mellitus — Journal of Veterinary Internal Medicine (published 2012-07, day not given in the PubMed record; accessed 2026-09-01). PMID 22646241 — https://pubmed.ncbi.nlm.nih.gov/22646241/ [peer-reviewed] [3] Acceptance of home blood glucose monitoring by owners of recently diagnosed diabetic cats and impact on quality of life changes in cat and owner — Journal of Feline Medicine and Surgery (published 2018-08, day not given in the PubMed record; accessed 2026-09-01). PMID 28911254 — https://pubmed.ncbi.nlm.nih.gov/28911254/ [peer-reviewed] [4] Monitoring of Diabetes Mellitus Using the Flash Glucose Monitoring System: The Owners' Point of View — Veterinary Sciences (published 2023, month not given in the PubMed record; accessed 2026-09-01). PMID 36977242 — https://pubmed.ncbi.nlm.nih.gov/36977242/ [peer-reviewed] [5] Complications associated with a flash glucose monitoring system in diabetic dogs — Canadian Journal of Veterinary Research (published 2023, month not given in the PubMed record; accessed 2026-09-01). PMID 37790268 — https://pubmed.ncbi.nlm.nih.gov/37790268/ [peer-reviewed] [6] Complications associated with a flash glucose monitoring system in diabetic cats — Journal of Feline Medicine and Surgery (published 2021, month not given in the PubMed record; accessed 2026-09-01). PMID 33078691 — https://pubmed.ncbi.nlm.nih.gov/33078691/ [peer-reviewed] [7] Owner experiences in treating dogs and cats diagnosed with diabetes mellitus in the United States — Journal of the American Animal Hospital Association (published 2014-07, day not given in the PubMed record; accessed 2026-09-01). PMID 24855090 — https://pubmed.ncbi.nlm.nih.gov/24855090/ [peer-reviewed] [8] Exemptions for device establishments — eCFR, Title 21 (issue 2026-08-31; accessed 2026-09-01). 21 CFR 807.65(b) — https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-B/section-807.65 [federal-registry] [9] Influence of hospital-induced stress on blood glucose concentrations, serum concentrations of cortisol, thyroxine and bile acids, and behaviour in cats — Journal of Feline Medicine and Surgery (published 2025, month not given in the PubMed record; accessed 2026-09-01). PMID 40230085 — https://pubmed.ncbi.nlm.nih.gov/40230085/ [peer-reviewed]
Well established: The purchaser row's general finding that cost is a recurring burden for a substantial share of diabetic-pet owners rests on two independent, non-affiliated surveys run nine years apart by different research groups [4][7] and is stated plainly in §3 for that reason; the specific percentages each survey reports remain single-source and are marked as such.
Thin: The prescriber row rests on one guideline document [1]. Each operator-row finding rests on exactly one study — two of them ([2][3]) using the same validated instrument (DIAQoL-pet) but in different species cohorts, so they are not treated as corroborating each other. [3] additionally carries a disclosed sponsor conflict (Zoetis, a glucometer manufacturer) and is marked [manufacturer] for that reason. The two placement-complication findings [5][6] are each a single retrospective chart review. The payer row's regulatory fact [8] and the patient row's stress study [9] are each a single source.
Rescoped from class 3: "Would veterinarians adopt an owner-facing monitoring device instead of a hospital-based glucose curve?" is not answerable. Its closest revealed-behaviour twin, which is answered above, is the guideline's own already-published position that home monitoring is "ideal but not mandatory" [1] — a stated preference in a governing document, not a prediction about future behaviour — combined with the owner-adoption rate already observed in one UK cohort, where 74% of owners took up home monitoring once instructed [3].
Out of scope: CPT descriptors, excluded both because they are AMA-licensed and, per the registry finding in this report [8], because no HCPCS/CPT structure applies to a device that sits outside FDA premarket review in the first place; jurisdictions other than the US, UK and EU (no connector reaches others); MAUDE narratives (no connector exists in this repo).
Not searched vs. not found: Not found, actively searched this pass: a veterinary-technician- specific incentive or workload literature distinct from owner or veterinarian incentives (queries run: "veterinary technician glucose curve labor time diabetic," "veterinary technician role glucose monitoring diabetic patient," "veterinary technician job satisfaction diabetes monitoring workload" — all returned zero PubMed records); clinic-side device markup, margin, or sensor resale-pricing economics (query run: "veterinary practice revenue diagnostic device markup device economics" — zero records); a telemedicine or remote-monitoring workflow study addressing veterinarian time specifically (query run: "telemedicine remote glucose monitoring veterinarian insulin dose adjustment" — zero records). Not retrieved beyond title/metadata: the 2010 AAHA Diabetes Management Guidelines (PMID 20439947) carries no abstract text in the PubMed record itself, so no content from it beyond its existence, journal, and year is used above.
[inference] None in this report. Every substantive line in §3 restates what a retrieved source itself says; the payer-row synthesis ("no source located in this pass names any third-party payer… every owner-reported cost figure… is described… as coming from the owner's own funds") restates what sources [4], [7], and [8] each independently say rather than adding a claim none of them makes.
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| The 2018 AAHA Diabetes Management Guidelines for Dogs and Cats state that owner capability to administer insulin, recognize inadequate control, and monitor blood glucose at home is "ideal but not mandatory" | 2 published | PMID 29314873 | User groups |
| In a UK survey of 101 owners of insulin-treated diabetic dogs using the DIAQoL-pet tool, 84% reported a negative quality-of-life impact from diabetes mellitus | 2 published | PMID 22646241 | User groups |
| In a UK study of 38 diabetic cats, 28/38 (74%) of owners entered a home-blood-glucose-monitoring group after standardised instruction, and DIAQoL-pet scores improved within that group at 1, 3 and 6 months but not in the non-monitoring group | 2 published | PMID 28911254 | User groups |
| In a 2014 survey of 834 US owners of diabetic dogs and cats, treatment was considered expensive by the majority of owners, and cat owners were more likely than dog owners to use home blood glucose monitoring | 2 published | PMID 24855090 | User groups |
| In a 2023 survey of 50 diabetic-pet owners using a flash glucose monitoring system, 36% reported the device's cost was difficult to afford long-term and 34% found purchasing the sensor challenging | 2 published | PMID 36977242 | User groups |
| Manufacturers of devices used solely for veterinary purposes are exempt from FDA device-establishment registration under 21 CFR 807.65(b) | 1 registry | 21 CFR 807.65(b) | User groups |
| In a retrospective review of 34 diabetic dogs, 13/34 (38%) of flash-glucose-monitoring-system placements had an associated complication, most frequently mild dermatologic change at the sensor site (18%) | 2 published | PMID 37790268 | User groups |
| In a retrospective review of 20 diabetic cats (33 sensor placements), 10/33 (30%) of flash-glucose-monitoring-system placements had an associated complication | 2 published | PMID 33078691 | User groups |